Prognostic value of cancer stem cells markers in triple-negative breast cancer

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Collina, Francesca ^a   Di Bonito, Maurizio ^a   Li Bergolis, Valeria ^a   De Laurentiis, Michelino ^a   Vitagliano, Carlo ^a   Cerrone, Margherita ^a   Nuzzo, Francesco ^a   Cantile, Monica ^a   Botti, Gerardo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CELL MARKER; HERMES ANTIGEN; TUMOR MARKER; CYTOKINE;

ADULT; ARTICLE; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; AGED; EPIDEMIOLOGY; IMMUNOLOGY; ITALY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREVALENCE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CYTOKINES; FEMALE; HUMANS; ITALY; MIDDLE AGED; NEOPLASTIC STEM CELLS; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84945415477     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/158682     Document Type: Article

References (34)

1. R. Schmadeka, B. E. Harmon, and M. Singh, "Triple-negative breast carcinoma: current and emerging concepts," American Journal of Clinical Pathology, vol. 141, no. 4, pp. 462-477, 2014.
2. S. Elsamany and S. Abdullah, "Triple-negative breast cancer: future prospects in diagnosis and management," Medical Oncology, vol. 31, no. 2, article 834, 2014.
3. H. J. Burstein, "Patients with triple negative breast cancer: is there an optimal adjuvant treatment?" Breast, vol. 22, no. 2, pp. S147-S148, 2013.
4. W. D. Foulkes, I. E. Smith, and J. S. Reis-Filho, "Triple-negative breast cancer," The New England Journal of Medicine, vol. 363, no. 20, pp. 1938-1948, 2010.
5. A. Prat, B. Adamo, M. C. U. Cheang, C. K. Anders, L. A. Carey, and C. M. Perou, "Molecular characterization of basal-like and non-basal-like triple-negative breast cancer," Oncologist, vol. 18, no. 2, pp. 123-133, 2013.
6. B. D. Lehmann, J. A. Bauer, X. Chen et al., "Identifcation of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies," The Journal of Clinical Investigation, vol. 121, no. 7, pp. 2750-2767, 2011.
7. M. D. Burstein, A. Tsimelzon, G. M. Poage et al., "Comprehensive genomic analysis identifes novel subtypes and targets of triple-negative breast cancer," Clinical Cancer Research, vol. 21, no. 7, pp. 1688-1698, 2015.
8. E. Charafe-Jaufret, C. Ginestier, F. Iovino et al., "Breast cancer cell lines contain functional cancer stem sells with metastatic capacity and a distinct molecular signature," Cancer Research, vol. 69, no. 4, pp. 1302-1313, 2009.
9. S.-Q. Geng, A. T. Alexandrou, and J. J. Li, "Breast cancer stem cells: Multiple capacities in tumor metastasis," Cancer Letters, vol. 349, no. 1, pp. 1-7, 2014.
10. N. Kagara, K. T. Huynh, C. Kuo et al., "Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer," American Journal of Pathology, vol. 181, no. 1, pp. 257-267, 2012.
11. H. J. Kim, M.-J. Kim, S. H. Ahn et al., "Diferent prognostic signifcance of CD24 and CD44 expression in breast cancer according to hormone receptor status," Breast, vol. 20, no. 1, pp. 78-85, 2011.
12. -/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome," Human Pathology, vol. 43, no. 3, pp. 364-373, 2012.
13. - phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients," Medical Oncology, vol. 28, no. 3, pp. 745-752, 2011.
14. + phenotype is a poor prognostic marker in early invasive breast cancer," Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 979-995, 2012.
15. K. M. Britton, R. Eyre, I. J. Harvey et al., "Breast cancer, side population cells and ABCG2 expression," Cancer Letters, vol. 323, no. 1, pp. 97-105, 2012.
16. H. Li, F. Ma, H. Wang et al., "Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer," International Journal of Biological Markers, vol. 28, no. 4, pp. e357-e364, 2013.
17. Y. S. Kim, M. J. Jung, D. W. Ryu, and C. H. Lee, "Clinicopatho-logic characteristics of breast cancer stem cells identifed on the basis of aldehyde dehydrogenase 1 expression," Journal of Breast Cancer, vol. 17, no. 2, pp. 121-128, 2014.
18. T. J. Liu, B. C. Sun, X. L. Zhao et al., "CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer," Oncogene, vol. 32, no. 5, pp. 544-553, 2013.
19. low phenotype and reduces the CD133-related invasive-ness," Molecular Cancer, vol. 12, no. 1, article 165, 2013.
20. P. Zhao, Y. Lu, X. Jiang, and X. Li, "Clinicopathological sig-nifcance and prognostic value of CD133 expression in triple-negative breast carcinoma," Cancer Science, vol. 102, no. 5, pp. 1107-1111, 2011.
21. R. Nadal, F. G. Ortega, M. Salido et al., "CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy," International Journal of Cancer, vol. 133, no. 10, pp. 2398-2407, 2013.
22. C. Bock, B. Rack, J. Huober, U. Andergassen, U. Jeschke, and S. Doisneau-Sixou, "Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients," Future Oncology, vol. 10, no. 10, pp. 1751-1765, 2014.
23. L. Xiang, P. Su, S. Xia et al., "ABCG2 is associated with HER-2 Expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma," Diagnostic Pathology, vol. 6, article 90, 2011.
24. K. Polyak, "Heterogeneity in breast cancer," Journal of Clinical Investigation, vol. 121, no. 10, pp. 3786-3788, 2011.
25. Y. Ohi, Y. Umekita, T. Yoshioka et al., "Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer," Histopathology, vol. 59, no. 4, pp. 776-780, 2011.
26. + cells with cancer stem cell characteristics," Breast Cancer Research, vol. 10, article R10, 2008.
27. Y. Wu and P. Y. Wu, "CD133 as a marker for cancer stem cells: progresses and concerns," Stem Cells and Development, vol. 18, no. 8, pp. 1127-1134, 2009.
28. A. Ieni, G. Giufrè, V. Adamo, and G. Tuccari, "Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas," Anticancer Research, vol. 31, no. 4, pp. 1315-1320, 2011.
29. J. M. V. Louderbough and J. A. Schroeder, "Understanding the dual nature of CD44 in breast cancer progression," Molecular Cancer Research, vol. 9, no. 12, pp. 1573-1586, 2011.
30. H. S. Berner, Z. Suo, B. Risberg, K. Villman, M. G. Karlsson, and J. M. Nesland, "Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas," Histopathology, vol. 42, no. 6, pp. 546-554, 2003.
31. B. D. Gun, B. Bahadir, S. Bektas et al., "Clinicopathological signifcance of fascin and CD44v6 expression in endometrioid carcinoma," Diagnostic Pathology, vol. 7, no. 1, article 80, 2012.
32. R. F. Torne, J. W. Legg, and C. M. Isacke, "The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events," Journal of Cell Science, vol. 117, no. 3, pp. 373-380, 2004.
33. A. Ouhtit, Z. Y. Abd Elmageed, M. E. Abdraboh, T. F. Lioe, and M. H. G. Raj, "In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver," American Journal of Pathology, vol. 171, no. 6, pp. 2033-2039, 2007.
34. J. I. Lopez, T. D. Camenisch, M. V. Stevens, B. J. Sands, J. McDonald, and J. A. Schroeder, "CD44 attenuates metastatic invasion during breast cancer progression," Cancer Research, vol. 65, no. 15, pp. 6755-6763, 2005.